Source link : https://www.newshealth.biz/health-news/confirmed-antitumor-activity-with-t-dxd-for-her2-positive-metastatic-crc/
The antibody-drug conjugate trastuzumab deruxtecan (T-DXd, Enhertu) proved active in a phase II study of advanced HER2-positive colorectal cancer (CRC). Almost 40% of patients treated with the recommended dose had objective responses and almost half had stable disease. The patients had a median progression-free survival (PFS) of 5.8 months and overall survival (OS) of 13.4 […]
Author : News Health
Publish date : 2024-08-16 21:37:47
Copyright for syndicated content belongs to the linked Source.
Categories